Considerations in Medicines

Considering biosimilars in inflammatory diseases



Key topics of interest have been identified through consultation and guidance from the expert scientific steering committee, consisting of nine Professors of Rheumatology, to ensure the educational activities are relevant and meet the learning needs of rheumatology specialists. The objective of these CME courses is to support their professional development and practice in the context of evolving management strategies for rheumatoid arthritis.

View journal
image

The biosimilar approval process: how different is it?

  • The biosimilar approval process: how different is it?
  • Discussion - Considering legal and regulatory aspects of biosimilar development
  • Discussion - Considering glycosylation and immunogenicity

image

Biosimilars already approved and in development

  • Biosimilars already approved and in development
  • Discussion - Considering biosimilar trials

image

Biosimilars: considerations for clinical practice

  • Biosimilars: considerations for clinical practice
  • Discussion - Access to biologic therapy with biosimilars
  • Discussion - Considering biosimilars in clinical practice
  • Discussion - Considering biosimilar safety monitoring

image

Considering biosimilar policy

  • Considering biosimilar policy
  • Discussion - Considering regulatory and collaboration considerations
  • Discussion - Considering what is important within extrapolation of indications

image

Considering biosimilars in inflammatory diseases summary discussion

  • Considering biosimilars in inflammatory diseases summary discussion


View my Achievements